Premium
Hepatitis C: When high drug prices preclude patient benefit
Author(s) -
Kantarjian Hagop M.,
Paul Shilpa
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31292
Subject(s) - medicine , drug , hepatitis , hepatitis c , hepatitis a , intensive care medicine , virology , surgery , pharmacology
Currently, there are at least 6 drug companies that have developed curative treatments for hepatitis C. Drugs that cure hepatitis C can save up to one‐half million individuals every year, but these therapies are neither accessible nor affordable. See also pages 1647‐49.